DURECT (DRRX) Competitors $1.91 0.00 (0.00%) As of 09/11/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. AVIR, VOR, OGI, PRQR, HRTX, TRDA, CABA, ACRS, VTYX, and TNXPShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Atea Pharmaceuticals (AVIR), Vor Biopharma (VOR), Organigram Global (OGI), ProQR Therapeutics (PRQR), Heron Therapeutics (HRTX), Entrada Therapeutics (TRDA), Cabaletta Bio (CABA), Aclaris Therapeutics (ACRS), Ventyx Biosciences (VTYX), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors Atea Pharmaceuticals Vor Biopharma Organigram Global ProQR Therapeutics Heron Therapeutics Entrada Therapeutics Cabaletta Bio Aclaris Therapeutics Ventyx Biosciences Tonix Pharmaceuticals DURECT (NASDAQ:DRRX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Which has better earnings and valuation, DRRX or AVIR? DURECT has higher revenue and earnings than Atea Pharmaceuticals. DURECT is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$1.66M35.80-$8.32M-$0.10-19.10Atea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.80 Which has more volatility and risk, DRRX or AVIR? DURECT has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Do insiders & institutionals hold more shares of DRRX or AVIR? 28.0% of DURECT shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 3.2% of DURECT shares are held by company insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer DRRX or AVIR? Atea Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 106.90%. Given Atea Pharmaceuticals' higher probable upside, analysts plainly believe Atea Pharmaceuticals is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Atea Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor DRRX or AVIR? In the previous week, DURECT's average media sentiment score of 0.00 equaled Atea Pharmaceuticals'average media sentiment score. Company Overall Sentiment DURECT Neutral Atea Pharmaceuticals Neutral Is DRRX or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to DURECT's net margin of -96.19%. Atea Pharmaceuticals' return on equity of -32.55% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-96.19% -259.16% -71.78% Atea Pharmaceuticals N/A -32.55%-30.47% SummaryAtea Pharmaceuticals beats DURECT on 8 of the 12 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.31M$2.66B$6.08B$10.56BDividend YieldN/A56.44%5.68%4.70%P/E Ratio-19.1024.2278.0526.71Price / Sales35.80590.33577.14179.08Price / CashN/A172.4737.7961.25Price / Book6.595.3412.556.56Net Income-$8.32M$32.92M$3.31B$277.70M7 Day PerformanceN/A3.90%4.28%2.41%1 Month PerformanceN/A10.60%7.85%9.30%1 Year Performance54.03%-3.95%71.37%31.22% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT1.0071 of 5 stars$1.91flatN/AN/A$59.31M$1.66M-19.1080Positive NewsAVIRAtea Pharmaceuticals1.8598 of 5 stars$2.92-0.3%$6.00+105.5%-12.9%$232.52MN/A-1.8170VORVor Biopharma1.0541 of 5 stars$39.89+18.6%N/AN/A$230.43MN/A-0.15140Short Interest ↓High Trading VolumeOGIOrganigram Global1.0607 of 5 stars$1.97+16.6%N/A+6.8%$227.04M$117.47M39.41860High Trading VolumePRQRProQR Therapeutics2.5211 of 5 stars$2.19+3.8%$8.00+265.3%+34.6%$222M$20.46M-4.76180Positive NewsHRTXHeron Therapeutics3.566 of 5 stars$1.27+5.0%$4.50+254.3%-36.2%$221.81M$149.69M-63.50300TRDAEntrada Therapeutics2.5039 of 5 stars$5.84+0.7%$25.67+339.5%-63.5%$220.62M$79.48M-3.28110News CoveragePositive NewsCABACabaletta Bio2.8147 of 5 stars$2.38+0.8%$14.50+509.2%-43.4%$215.86MN/A-0.8850News CoverageACRSAclaris Therapeutics3.0014 of 5 stars$1.92-3.5%$8.71+353.9%+56.3%$215.58M$18.72M-1.40100VTYXVentyx Biosciences1.6695 of 5 stars$3.03+1.7%$7.50+147.5%+74.8%$212.50MN/A-1.8030News CoverageGap UpTNXPTonix Pharmaceuticals2.9675 of 5 stars$24.76+2.3%$70.00+182.7%+90.5%$212.22M$10.09M-0.6350Analyst Downgrade Related Companies and Tools Related Companies AVIR Competitors VOR Competitors OGI Competitors PRQR Competitors HRTX Competitors TRDA Competitors CABA Competitors ACRS Competitors VTYX Competitors TNXP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRRX Stock Alerts